DDrare: Database of Drug Development for Rare Diseases

40. 高安動脈炎
［臨床試験数：22，薬物数：46（DrugBank：20），標的遺伝子数：22，標的パスウェイ数：111］

Searched query = "Takayasu arteritis", "Aortitis syndrome", "Pulseless disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = AZA; Acetate; Adalimumab; Anti-thymocyte globulin; CYC; Clofarabine; Cyclophosphamide; Cyclosporine; DCB; Filgrastim; Glucocorticoids; INFLIXIMAB; Infliximab; Leflunomide; Leflunomide 10mg Tab; MMF; MTX; Methotrexate; Methotrexate Tablets; Methylprednisolone; Naltrexone; Naltrexone Hydrochloride; Placebo; Prednisolone; Prednisone; Prednisone Acetate; Prednisone acetate; Prednisone, cyclophosphamide; Procedure: Autologous Peripheral Blood Stem Cell Transplantation; Procedure: Computed Tomography; Procedure: Digital substraction angiography (DSA); Procedure: Drug coated balloon (DCB); Procedure: Positron Emission Tomography; Radiation: Fluorine F 18 Clofarabine; Remicade; Remicade (anti tumor necrosis factor inhibitor); RoActemra; RoActemra 20mg/ml; TOCILIZUMAB; Tocilizumab; Tocilizumab (MRA-SC); Tofacitinib; Tofacitinib tablet; Upadacitinib; Yellow Fever Vaccine; Yellow Fever vaccine (17D)

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04161898 (ClinicalTrials.gov)	February 4, 2020	12/11/2019	A Study to Evaluate the Efficacy and Safety of Upadacitinib in Subjects With Takayasu Arteritis (TAK)	A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Upadacitinib in Subjects With Takayasu Arteritis (SELECT-Takayasu)	Takayasu Arteritis (TAK)	Drug: Upadacitinib;Drug: Placebo for Upadacitinib;Drug: Prednisolone	AbbVie	NULL	Recruiting	18 Years	N/A	All	56	Phase 3	Japan;Korea, Republic of
2	NCT03482479 (ClinicalTrials.gov)	February 4, 2019	22/3/2018	Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis	Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis	Eosinophilic Granulomatosis With Polyangiitis (EGPA);Churg-Strauss Syndrome (CSS);Giant Cell Arteritis;Granulomatosis With Polyangiitis;Microscopic Polyangiitis;Polyarteritis Nodosa;Takayasu Arteritis	Drug: Naltrexone Hydrochloride;Other: Placebo Comparator	University of Pennsylvania	NULL	Recruiting	18 Years	N/A	All	36	Phase 2	United States
3	NCT02981979 (ClinicalTrials.gov)	December 2016	22/11/2016	Takayasu Arteritis Clinical Trial in China	Comparison of the Efficacy and Safety of Leflunomide Versus Placebo Combine With the Basic Prednisone Therapy in Patients With Active Phase of Takayasu's Arteritis: a Randomized Controlled Double-blinded Trial	Takayasu Arteritis	Drug: Leflunomide 10mg Tab;Drug: Prednisone Acetate;Drug: Placebos	Jiang lindi	NULL	Unknown status	18 Years	65 Years	All	116	N/A	China
4	JPRN-JapicCTI-142616	02/10/2014	23/07/2014	Phase III Study of MRA-SC in Patients with Takayasu Arteritis	A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase III Study of MRA-SC in Patients with Takayasu Arteritis	Takayasu Arteritis	Intervention name : tocilizumab (MRA-SC) INN of the intervention : tocilizumab Dosage And administration of the intervention : 162mg/W, SC Control intervention name : Placebo INN of the control intervention : - Dosage And administration of the control intervention : Placebo/W, SC	Chugai Pharmaceutical Co., Ltd.	NULL	complete	12		BOTH	34	Phase 3	Japan

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT04161898
(ClinicalTrials.gov)

February 4, 2020

12/11/2019

A Study to Evaluate the Efficacy and Safety of Upadacitinib in Subjects With Takayasu Arteritis (TAK)

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Upadacitinib in Subjects With Takayasu Arteritis (SELECT-Takayasu)

Takayasu Arteritis (TAK)

Drug: Upadacitinib;Drug: Placebo for Upadacitinib;Drug: Prednisolone

AbbVie

NULL

Recruiting

18 Years

N/A

All

Phase 3

Japan;Korea, Republic of

NCT03482479
(ClinicalTrials.gov)

February 4, 2019

22/3/2018

Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis

Eosinophilic Granulomatosis With Polyangiitis (EGPA);Churg-Strauss Syndrome (CSS);Giant Cell Arteritis;Granulomatosis With Polyangiitis;Microscopic Polyangiitis;Polyarteritis Nodosa;Takayasu Arteritis

Drug: Naltrexone Hydrochloride;Other: Placebo Comparator

University of Pennsylvania

NULL

Recruiting

18 Years

N/A

All

Phase 2

United States

NCT02981979
(ClinicalTrials.gov)

December 2016

22/11/2016

Takayasu Arteritis Clinical Trial in China

Comparison of the Efficacy and Safety of Leflunomide Versus Placebo Combine With the Basic Prednisone Therapy in Patients With Active Phase of Takayasu's Arteritis: a Randomized Controlled Double-blinded Trial

Takayasu Arteritis

Drug: Leflunomide 10mg Tab;Drug: Prednisone Acetate;Drug: Placebos

Jiang lindi

NULL

Unknown status

18 Years

65 Years

All

116

N/A

China

JPRN-JapicCTI-142616

02/10/2014

23/07/2014

Phase III Study of MRA-SC in Patients with Takayasu Arteritis

A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase III Study of MRA-SC in Patients with Takayasu Arteritis

Takayasu Arteritis

Intervention name : tocilizumab (MRA-SC)
INN of the intervention : tocilizumab
Dosage And administration of the intervention : 162mg/W, SC
Control intervention name : Placebo
INN of the control intervention : -
Dosage And administration of the control intervention : Placebo/W, SC

Chugai Pharmaceutical Co., Ltd.

NULL

complete

BOTH

Phase 3

Japan